TherapeuticsMD, Inc. (TXMD)
TXMD Stock Price Chart
Explore TherapeuticsMD, Inc. interactive price chart. Choose custom timeframes to analyze TXMD price movements and trends.
TXMD Company Profile
Discover essential business fundamentals and corporate details for TherapeuticsMD, Inc. (TXMD) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
9 May 2007
Employees
1.00
Website
https://www.therapeuticsmd.comCEO
Marlan D. Walker
Description
TherapeuticsMD, Inc. is a U.S.-based pharmaceutical company dedicated to women's health. Its marketed portfolio includes IMVEXXY, prescribed for moderate to severe dyspareunia; BIJUVA, a bio-identical hormone replacement therapy combining 17ß-estradiol and progesterone, used to alleviate moderate to severe vasomotor symptoms; and ANNOVERA, an innovative vaginal ring designed for contraception. In its developmental pipeline, TherapeuticsMD is advancing several preclinical candidates: TX-005HR, a transdermal cream containing only progesterone; TX-006HR, another transdermal cream formulated with both estradiol and progesterone; TX-007HR and TX-008HR, both experimental transdermal patches; and TX-009HR, an oral formulation of progesterone and estradiol. Beyond its core pharmaceutical offerings, the company produces and distributes both branded and generic prescription prenatal vitamins, notably under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 labels. Its prescription medications and prenatal vitamin lines reach consumers through established channels, including wholesale and retail pharmacy distributors. Established in 2008, TherapeuticsMD, Inc. maintains its corporate headquarters in Boca Raton, Florida.
TXMD Financial Timeline
Browse a chronological timeline of TherapeuticsMD, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 17 Aug 2026
EPS estimate is -$5.50, while revenue estimate is $22.11m.
Earnings released on 12 May 2026
EPS came in at $0.01 surpassing the estimated -$6.13 by +100.16%, while revenue for the quarter reached $724.00k , missing expectations by -96.34%.
Earnings released on 30 Mar 2026
EPS came in at -$0.05 falling short of the estimated $0.04 by -233.75%, while revenue for the quarter reached $893.00k , missing expectations by -61.17%.
Earnings released on 12 Nov 2025
EPS came in at $0.01 , while revenue for the quarter reached $784.00k .
Earnings released on 12 Aug 2025
EPS came in at $0.05 , while revenue for the quarter reached $952.00k .
Earnings released on 13 May 2025
EPS came in at -$0.06 , while revenue for the quarter reached $393.00k .
Earnings released on 27 Mar 2025
EPS came in at $0.02 falling short of the estimated $0.04 by -45.38%, while revenue for the quarter reached $667.00k , missing expectations by -71.00%.
Earnings released on 12 Nov 2024
EPS came in at -$0.05 falling short of the estimated $0.04 by -225.00%, while revenue for the quarter reached $547.00k , missing expectations by -76.22%.
Earnings released on 12 Aug 2024
EPS came in at -$0.09 falling short of the estimated $0.03 by -400.00%, while revenue for the quarter reached $234.00k , missing expectations by -53.20%.
Earnings released on 10 May 2024
EPS came in at -$0.07 falling short of the estimated $0.03 by -333.33%, while revenue for the quarter reached $313.00k , missing expectations by -37.40%.
Earnings released on 29 Mar 2024
EPS came in at -$0.08 surpassing the estimated -$0.13 by +38.46%, while revenue for the quarter reached $502.00k , beating expectations by +0.40%.
Earnings released on 14 Nov 2023
EPS came in at -$0.13 surpassing the estimated -$0.15 by +13.33%, while revenue for the quarter reached -$53.00k , missing expectations by -110.60%.
Earnings released on 14 Aug 2023
EPS came in at -$0.24 falling short of the estimated -$0.07 by -242.86%, while revenue for the quarter reached $437.00k , missing expectations by -12.60%.
Earnings released on 15 May 2023
EPS came in at -$0.24 falling short of the estimated $0.06 by -500.00%, while revenue for the quarter reached $416.00k , missing expectations by -75.53%.
Earnings released on 27 Mar 2023
EPS came in at -$3.55 falling short of the estimated -$1.11 by -219.55%, while revenue for the quarter reached $1.15m , missing expectations by -95.16%.
Earnings released on 14 Nov 2022
EPS came in at -$3.13 falling short of the estimated -$2.04 by -53.43%, while revenue for the quarter reached $20.92m , missing expectations by -21.95%.
Earnings released on 15 Aug 2022
EPS came in at -$2.15 surpassing the estimated -$3.04 by +29.28%, while revenue for the quarter reached $28.56m , beating expectations by +23.11%.
Earnings released on 16 May 2022
EPS came in at -$4.72 falling short of the estimated -$3.50 by -34.86%, while revenue for the quarter reached $19.33m , beating expectations by +7.67%.
Stock split effective on 9 May 2022
Shares were split 1 : 50 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 10 Mar 2022
EPS came in at -$4.50 falling short of the estimated -$3.00 by -50.00%, while revenue for the quarter reached $18.68m , missing expectations by -36.45%.
Earnings released on 11 Nov 2021
EPS came in at -$5.50 falling short of the estimated -$5.00 by -10.00%, while revenue for the quarter reached $25.41m , missing expectations by -1.80%.
Earnings released on 4 Aug 2021
EPS came in at -$5.50 matching the estimated -$5.50, while revenue for the quarter reached $23.00m , meeting expectations.
TXMD Stock Performance
Access detailed TXMD performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
